Diabetic foot ulcers are slow-healing and increase the risk of infections and amputation. Researchers at Karolinska ...

Feb 9 (Reuters) - Eli Lilly will buy therapy developer Orna Therapeutics for up to $2.4 billion in cash, the companies said ...

Orna’s ORN-252 is a clinical trial-ready CAR-T therapy that targets CD19, a critical cell surface protein to treat B ...

Researchers at Karolinska Institutet have identified a circular RNA in mitochondria that plays an important role in the ...

Circular Genomics, a molecular diagnostics company pioneering circular RNA (circRNA)–based biomarkers for neurodegenerative disease, today announced the completion of exclusive intellectual property ...

Eli Lilly (LLY) stock acquiring Orna Therapeutics for up to $2.4 billion to develop circular RNA CAR-T therapies for B ...

Eli Lilly reinforced its push into next-generation immunology and oncology innovation through two major transactions: the ...

Over the past few decades, RNA’s place in biology has transformed from being a mere intermediate between DNA and protein to a fascinating molecule with diverse activities that go well beyond simple ...

Deep within our nerve cells, a molecule is at work that has no beginning and no end. Instead of a straight chain, as is common for most RNA strands, it forms a closed loop. Known as circular RNAs ...

A new review article highlights the transformative role of circular RNA (circRNA) in cancer, revealing its potential as both a key player in tumor biology and a promising avenue for future therapies.